



## Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress

June 18, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun. 18, 2020--Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company's participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.

Personalis will present "Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform" in an [industry-sponsored symposium](#), featuring the Personalis universal cancer immunogenomics platform, [ImmunID NeXT](#). Erin Newburn, MS, PhD, will present for Personalis.

Dr. Newburn will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, and oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status. In addition, Dr. Newburn will present a recent case study from a cohort of metastatic melanoma patients who were treated with an immune checkpoint blockade, where we integrated several different molecular features from the ImmunID NeXT Platform™ to help better define the responder and non-responder patients.

### About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis [ImmunID NeXT Platform](#)™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis [Clinical Laboratory](#) is GxP-aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit [www.personalis.com](http://www.personalis.com) and follow Personalis on Twitter ([@PersonalisInc](#)).

### Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts, including, for example, statements regarding the future availability, features or potential uses of the ImmunID NeXT Platform and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis' filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200618005949/en/): <https://www.businesswire.com/news/home/20200618005949/en/>

### Investor Relations Contact for Personalis:

Caroline Corner  
[investors@personalis.com](mailto:investors@personalis.com)  
415-202-5678

### Media Contact for Personalis:

Jennifer Havlek  
[pr@personalis.com](mailto:pr@personalis.com)  
[www.personalis.com](http://www.personalis.com)  
650-752-1300

Source: Personalis, Inc.